Genentech To Acquire Portfolio Of Next-generation CDK Inhibitors From Regor - Quick Facts
(RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer. Regor will receive an upfront cash payment of $850 million and is eligible to receive additional cash payments. Genentech will be responsible for clinical development, manufacturing and commercialization.
Regor Pharmaceuticals USA is part of Regor Therapeutics Group, a clinical-stage biotechnology company developing clinically differentiated medicines to address large unmet needs in oncology, metabolism and auto-immunity.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.